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Autophagy modulationily conserved process whereby cytoplasm and cellular organelles are degraded in
lysosomes for amino acid and energy recycling. Autophagy is a survival pathway activated in response to
nutrient deprivation and other stressful stimuli, such as metabolic stress and exposure to anticancer drugs.
However, autophagy may also result in cell death, if it proceeds to completion. Defective autophagy is
implicated in tumorigenesis, as the essential autophagy regulator beclin 1 is monoallelically deleted in
human breast, ovarian and prostate cancers, and beclin 1+/− mice are tumor-prone. How autophagy
suppresses tumorigenesis is under intense investigation. Cell-autonomous mechanisms, involving protection
of genome integrity and stability, and a non-cell-autonomous mechanism, involving suppression of necrosis
and inﬂammation, have been discovered so far. The role of autophagy in treatment responsiveness is also
complex. Autophagy inhibition concurrently with chemotherapy or radiotherapy has emerged as a novel
approach in cancer treatment, as autophagy-competent tumor cells depend on autophagy for survival under
drug- and radiation-induced stress. Alternatively, autophagy stimulation and preservation of cellular ﬁtness
by maintenance of protein and organelle quality control, suppression of DNA damage and genomic instability,
and limitation of necrosis-associated inﬂammation may play a critical role in cancer prevention.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Macroautophagy, hereafter referred to as autophagy, is a cellular
self-consumption process characterized by sequestration of bulk
cytoplasm, long-lived proteins and cellular organelles in double-
membrane vesicles called autophagosomes, which are delivered to
and degraded in lysosomes [1]. Basal autophagy plays an important
role in cellular homeostasis by degrading excessive, damaged and/or
aged proteins and organelles, and thus maintaining quality control of
essential cellular components [2,3]. Defective autophagy has been
implicated in the pathogenesis of diverse disease states, such as
myopathy [4], neuronal degeneration [5], microbial infection [6],
inﬂammatory bowel disease [7,8], aging [9] and cancer [10]. In addition
to its basal function, autophagy is readily induced in response to nutrient
deprivation [11–14], metabolic stress [15–17], endoplasmic reticulum
(ER)-stress [18,19], radiation [20] and anticancer drugs [21–24]. The
role of autophagy as an alternate energy source, and thus as a
temporary survival mechanism, under stressful conditions is well
recognized [25]. The presence of autophagosomes in dying cells raises
the possibility that autophagy may also play an active role in cell death
[26]. However, in most occasions, it is unclear whether this is the caseJersey, 195 Little Albany Street,
35 8617; fax: +1732 235 6797.
adsworth).
ll rights reserved.or autophagy is just a bystander merely representing the cell's
desperate attempt to sustain survival upon severe stress and/or injury.
The mechanism by which defective autophagy contributes to
tumorigenesis is under intense investigation. Inactivation of apopto-
sis, and thus deregulation of cell death, is a frequent occurrence in
tumor cells [27], indicating that aberrant cell survival and cell death
drive cancer progression. Loss of a survival pathway, such as
autophagy, might have then been expected to undermine tumorigen-
esis; however, the recognition of the essential autophagy regulator
beclin 1 as a haploinsufﬁcient tumor suppressor [28,29] argues against
this simplistic scenario.
In this publication, the role of autophagy in tumorigenesis and the
possible implications of the functional status of autophagy on
treatment responsiveness will be reviewed. What is currently known
on the regulation of autophagy in tumor cells will also be presented,
together with a discussion on how pharmacologic modulation of
autophagy may lead to improved combinatorial anticancer regimens.
2. beclin 1 as a haploinsufﬁcient tumor suppressor
The autophagy-related (atg) genes play essential roles at different
stages of the autophagic process, including induction, vesicle forma-
tion, and autophagosome degradation, and were ﬁrst identiﬁed and
characterized in yeast [30]. Autophagy is evolutionarily conserved,
and many yeast Atg proteins have homologues in higher eukaryotes.
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atg6/VPS30 gene, which is required for both autophagy and sorting of
the vacuole resident hydrolase carboxypeptidase Y through the Vps
pathway [31]. The possibility that defective autophagy may play a role
in cancer was ﬁrst recognized through studies focused on Beclin 1, as
summarized below.
beclin 1 was originally discovered during the positional cloning of
BRCA1 and was entered in GenBank as a gene of unknown function
[32]. Beclin 1 was independently rediscovered in a yeast two-hybrid
screen of an adult mouse brain library as a Bcl-2 interacting protein
[33]. beclin 1 maps to a centromeric region of BRCA1 on chromosome
17q21 that is commonly deleted in 75, 50 and 40% of ovarian, breast,
and prostate cancers, respectively [34–38]. In addition to beclin 1, this
commonly deleted region contains at least 11 more genes, 6 genes of
known function and not considered cancer-related, and 5 completely
novel genes. FISH analysis of human breast cancer cell lines using the
beclin 1-containing PAC 452O8 as a probe revealed that 9 out of 22 cell
lines had allelic beclin 1 deletions [39]. The cell lines examined were
mostly aneuploidwith 3–7 copies of chromosome 17 and showed only
a “partial” beclin 1 deletion, still retaining 2–3 copies of beclin 1.
Sequencing of the retained beclin 1 alleles did not reveal any
mutations, and, interestingly, Beclin 1 mRNA levels were comparable
in all cell lines, independently of beclin 1 copy number [39]. The
autophagy potential of these cell lines has been only marginally
characterized so far [40,41].
Ectopic expression of Beclin 1 restores full autophagy potential in
MCF-7 cells, which are tetraploid, but have three beclin 1 copies, and
slows cell proliferation in vitro and in xenograft tumors in vivo [41].
This ﬁnding together with the frequent allelic deletion of beclin 1 in
human breast cancer cell lines raised the possibility that beclin 1 may
be a tumor suppressor, a hypothesis subsequently conﬁrmed by
knockout mouse technology. beclin 1 heterozygous mice develop
lymphomas, liver and lung cancers as they age, as well as
hyperproliferative, preneoplastic mammary lesions [29,42]. The
second beclin 1 allele is retained in all tumors developing in beclin
1+/− mice, and is neither mutated nor silenced [28], indicating that
beclin 1 is a haploinsufﬁcient tumor suppressor. Monoallelic beclin 1
loss also accelerates the development of hepatitis B virus-induced
premalignant liver lesions [28]. Furthermore, beclin 1+/− immorta-
lized babymouse kidney (iBMK) cells [15,17] and immortalizedmouse
mammary epithelial cells (iMMECs) [16], which exhibit compromised
autophagy under metabolic stress, display accelerated tumorigenesis
in nude mouse allografts.
Lower Beclin 1 protein expression, as compared to Beclin 1 levels in
normal adjacent breast tissue, was conﬁrmed in a small series of
human breast tumors [41], but any correlation between allelic beclin 1
loss, and thus defective autophagy, and clinical outcome in breast
cancer remains to be investigated. Decreased Beclin 1 mRNA and
protein expressionwas also demonstrated in glioblastomamultiforme
(GBM) and other high-grade brain tumors [43]. In contrast, higher
expression of Beclin 1 was detected in the majority of colorectal (95%)
and gastric (83%) carcinomas examined as compared to the normal
stomach and colon mucosa, which show very low or undetectable
Beclin 1 levels [44]. In this case, Beclin 1 expression did not show any
correlation with pathological and clinical characteristics, such as
stage, invasion, and metastasis [44]. It is, therefore, conceivable that
the tumor suppressive function of Beclin 1 may be tissue-speciﬁc,
which is certainly worthy of further investigation.
3. The Beclin 1 protein network
As mentioned earlier, Beclin 1 was originally identiﬁed as a Bcl-2
interacting protein in a yeast two-hybrid system [33]. This interaction
is not very surprising, given that Beclin 1 possesses a putative Bcl-2-
homology-3 (BH3) amphipathic alpha-helix (amino acids 112–123),
as demonstrated by X-ray crystallography [45], NMR spectroscopy[46], and mutational analysis [47], which can interact with the BH3
receptor domain (hydrophobic grove) of the anti-apoptotic proteins
Bcl-2, Bcl-xL, Bcl-w, and to a lesser extent Mcl-1 [48]. Binding of Beclin
1 to Bcl-2 or Bcl-xL is much weaker than that of proapoptotic BH3-
only proteins, such as Bid, Bad, Bak, and Bim [46]. Upon nutrient
deprivation, which is the most potent autophagy inducer, BH3-only
proteins induce autophagy by competitively disrupting the interaction
between Beclin 1 and Bcl-2 or Bcl-xL [49]. At this point, it is unclear
whether the autophagy-inhibitory Beclin 1–Bcl-2 or Beclin 1–Bcl-xL
interaction plays any role in the tumor promoting function of the anti-
apoptotic Bcl-proteins, especially since only endoplasmic reticulum
(ER)-targeted Bcl-2 binds Beclin 1 and the interaction between these
two proteins is disrupted under conditions of metabolic stress, which
is a frequent occurrence in tumors in vivo.
The role of autophagy in tumor suppression has further been
established by the identiﬁcation and characterization of Beclin 1-
interacting proteins. Co-immunoprecipitation studies have identiﬁed
class III phosphoinositide-3-kinase (PI3KIII)/Vps34 as a major
physiological partner of Beclin 1 in a complex required for autophagy
initiation [50] and tumor suppression [51]. The UV irradiation
resistance-associated gene protein, UVRAG, interacts with Beclin 1
and PI3KIII to promote autophagosome formation, autophagy activa-
tion and inhibition of human colon cancer cell proliferation and
tumorigenicity [52]. UVRAG was recently shown to disrupt an in vitro
and in vivo observed Beclin 1-dimer interface, normally stabilized by
Bcl-2-like proteins, to induce autophagy [53]. Similarly to beclin 1,
UVRAG is monoallelically deleted in human colon cancers [52].
Furthermore, a polyadenine tract in the UVRAG gene (A10 in exon 8)
is a target for frameshift mutations decreasing the autophagy
potential of colon [54] and gastric [55] cancers with microsatellite
instability (MSI).
Bif-1, also known as SH3GLB1 or Endophilin B1, was originally
discovered as a Bax-binding protein [56,57], and was subsequently
shown to associate with membranes of intracellular organelles, such
as the Golgi apparatus [58,59] and mitochondria [60,61], and
participate in vesicle formation and membrane dynamics. More
recently, Bif-1 was identiﬁed as a Beclin 1-interacting protein through
UVRAG, a PI3KIII activator, and thus a regulator of autophagosome
formation, and a novel tumor suppressor, as bif-1−/− mice develop
lymphomas and solid tumors at about 12 months of age [62].
4. Other autophagy-related genes as tumor suppressors
Whereas beclin 1−/− mice die early in embryogenesis [28,29],
atg5−/− and atg7−/− mice are born normally, but die soon after
birth [11,12]. Also, in contrast to aging beclin 1+/− mice which are
tumor-prone, older atg5+/− and atg7+/− mice do not develop
malignancies, and neither tumorigenesis nor enhanced cell prolifera-
tion is observed in atg7-deﬁcient liver, which is abnormally large
mostly due to hepatocyte swelling [11]. These studies indicate that
Beclin 1 may play a more important role in embryonic development
and tumor suppression than Atg5 and Atg7 or, alternatively, that
autophagy-independent properties of Beclin 1 may be responsible for
these functions. More recently, atg5−/− iBMK cells were found to be
more tumorigenic than atg5+/− and atg5+/+ iBMK cells in nude
mouse allografts [17], suggesting that autophagy defects indeed play a
role in tumorigenesis. This was further conﬁrmed by the ﬁnding that
mice deﬁcient in atg4C/autophagin-3, a cysteine protease involved in
Atg8/LC3 processing required for autophagy execution [63], show
increased susceptibility to chemical carcinogen-induced ﬁbrosarcoma
development [64].
5. How does autophagy suppress tumorigenesis?
The mechanism by which autophagy defects lead to accelerated
tumorigenesis is not readily apparent, especially given the well-
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normal and tumor cell survival undermetabolic stress [25,65]. How loss
of a survival pathway promotes tumorigenesis presents an intriguing
paradox. Recent studies have revealed involvement of both non-cell-
autonomous and cell-autonomous mechanisms [65], and have pro-
vided insight into the role of autophagy in tumor suppression.
5.1. Non-cell-autonomous mechanism
While functional autophagy acts as a metabolic stress buffer, the
combined impairment of both apoptosis and autophagy promotes
necrotic cell death in vitro and in tumors in vivo [15]. Thus, autophagy
defects impair survival of apoptosis-defective tumor cells upon
nutrient and oxygen limitation, leading to cell death by necrosis,
which in turn is associated with inﬂammatory cell recruitment,
cytokine production and nuclear factor κB (NFκB) activation, which
has been linked to accelerated tumor growth [66]. Thus, autophagy
may function in tumor suppression by mitigating metabolic stress
and, in concert with apoptosis, by preventing tumor cell death by
necrosis. However, the speciﬁc interactions between necrotic tumors,
their microenvironment and the immune system, as well as the
speciﬁc molecular pathways implicated in tumorigenesis under these
conditions, have yet to be elucidated.
5.2. Cell-autonomous mechanism
An alternative, and likely complementary, mechanism by which
autophagy suppresses tumorigenesis involves its unique role in
preservation of cellular ﬁtness and genome integrity. Autophagy
defects are associated with accumulation of 1) ubiquitin-positive
protein aggregates in neurons and liver [67], 2) deformed, and likely
dysfunctional, cellular organelles, such as mitochondria [11] and
peroxisomes [68], and 3) DNA damage and genomic instability in
tumor cells with inactivated cell cycle checkpoints [16,65]. AlthoughFig. 1. Autophagy regulation. Growth factor signaling activates the PI3K/AKT/mTOR axis
antagonists inhibiting growth factor receptors, lithium and carbamazepine negatively regula
AKT activation, and rapamycin, RAD001 and CCI-779 inhibiting mTOR play pivotal roles in a
PI3K inhibitors such as 3-MA, wortmannin, LY294002 or PX-866 suppress autophagy. At least
stress: one mediated by AMPK and CaMKK, and the other involving p53 and damage-regula
exhibits dual function as both an autophagy inhibitor (via class I PI3K activation) and an authe exact mechanism by which autophagy limits genome damage has
not yet been determined, several hypotheses are being actively
investigated, including maintenance of energy balance and/or pre-
vention of oxidative stress, potentially caused by defective organelles
and accumulated unfolded proteins in autophagy-deﬁcient cells.
6. Regulation of autophagy in cancer
In normal cells, the mammalian target of rapamycin (mTOR)
kinase, which is downstream of the nutrient-sensor PI3K, primarily
regulates autophagy. In response to nutrient and growth factor
availability, the PI3K/AKT/mTOR axis is activated leading to suppres-
sion of autophagy and stimulation of cell proliferation. To the contrary,
starvation suppresses the PI3K pathway and de-represses autophagy,
which can now takeover as an alternate process for energy and amino
acid generation to sustain cell survival, at least temporarily. Regulation
of autophagy in tumors is governed by similar principles, only in a
much more complicated manner, given the frequently observed
abnormal PI3K activation in cancer and the multitude of interactions
between the PI3K/AKT/mTOR pathway and other cell signaling
cascades, often also deregulated in tumor cells.
6.1. The PI3K/AKT/mTOR pathway
Constitutive activation of the PI3K/AKT/mTOR axis is a prototypic
survival mechanism commonly encountered in human cancer [69].
Diverse cellular events, such as loss of the tumor suppressors
phosphatase and tensin-homolog deleted on chromosome 10
(PTEN) and tuberous sclerosis complex (TSC) 1 and TSC2, ampliﬁca-
tion or mutation of class I PI3K, overexpression of AKT, constitutive
activation of tyrosine kinase growth factor receptors and exposure to
carcinogens, can all result in abnormal activation of this pathway [70–
73] and, ultimately, in autophagy suppression [74,75] (Fig. 1). To the
contrary, G-protein coupled receptor (GPCR) antagonists to growthresulting in autophagy inhibition. Consequently, G-protein coupled receptor (GPCR)
ting class I PI3K, perifostine and AKT/PKB signaling inhibitor-2 (API-2) downregulating
utophagy upregulation. In contrast, class III PI3K activates autophagy, and thus class III
two pathways are responsible for autophagy activation in response to starvation and ER
ted autophagy modulator (DRAM) activation. In this complex regulatory network, Ras
tophagy activator (via the RAF1/MEK1/2/ERK1/2 pathway).
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carbamazepine, AKT inhibitors such as perifostine and AKT/PKB
signaling inhibitor-2 (API-2), and mTOR inhibitors such as rapamycin,
RAD-001 and CCI-779, result in autophagy induction and provide
multiple means for autophagy modulation in cancer treatment (Fig.
1).
Howmuch, if any, of the tumorigenicity conferred by the activated
class I PI3K pathway is due to autophagy inhibition is not currently
known. A deregulated PI3K/AKT/mTOR axis not only suppresses
autophagy, but also induces protein translation, cell growth and
proliferation, a major driving force in tumorigenesis. Tumors with
high metabolic demands, such as those with constitutively active PI3K
mutations, PTEN loss or AKT activation, would be expected to be
dependent on autophagy for energy homeostasis and survival. Thus,
suppression of autophagy by the PI3K signaling cascade presents a
disadvantage that these rapidly proliferating tumor cells may have to
overcome to remain viable, and leads to the prediction that
compensatory mechanisms, such as deregulated apoptosis and/or
metabolism, may be concurrently activated to counteract the negative
implications of defective autophagy on tumor cell survival. Two more
predictions pertain to the nature of the resultant apoptosis-and-
autophagy doubly-defective tumors: ﬁrst, necrosis and inﬂammation
may be prominent features of these tumors, a hypothesis already
conﬁrmed in tumors generated by apoptosis-deﬁcient iBMK cells
expressing activated AKT [15], and second, tumors resulting from PI3K
pathway activation may exhibit higher levels of DNA damage and
genomic instability, as autophagy defects compromise genome
integrity and stability, especially when apoptosis and cell-cycle
checkpoints have also been inactivated [16,17], a common ﬁnding in
PTEN-deﬁcient tumors [76], but, to this point in time, it is unclear if
this is autophagy-related.
In contrast to class I PI3K, class III PI3K induces autophagy in a
complex with Beclin 1, and thus class III PI3K inhibitors, such as
methyl-adenine (3-MA), wortmannin, LY294002 and PX-866, inhibit
autophagy (Fig. 1).
6.2. Role of p53
The relationship between p53 and autophagy is complex, as p53
appears to have a dual role in autophagy regulation [77]. The tumor
suppressor p53 is a critical checkpoint protein in mammalian cells
[78] which is activated under genotoxic stress conditions, including
DNA damage, hypoxia and oncogene activation, and responds by
initiating tumor suppression mechanisms, such as cell cycle arrest,
senescence and apoptosis. Under these conditions, p53 has been
shown to transactivate autophagy-inducing genes and stimulate
autophagy by inhibiting mTOR in an AMP-activated protein kinase
(AMPK)- and TSC1/TSC2-dependent manner [79,80]. This is, in turn,
accomplished by the LKB1-mediated activation of AMPK by an
increased AMP/ATP ratio [81,82]. p53 also induces autophagy via its
direct target damage-regulated autophagy modulator (DRAM) [83]
(Fig. 1). At the same time, however, genetic or pharmacologic
inactivation of cytoplasmic p53 also triggers autophagy [84], indicat-
ing that the non-nuclear p53 pool is a potent autophagy repressor.
Thus, autophagy is activated as a stress-mitigatingmechanism by both
stress-mediated p53 induction and stress-exacerbating p53 loss. The
circumstances and the molecular pathways involved in the decision to
use p53 for autophagy activation versus inhibition in cancer cells have
not yet been determined. Plausibly, p53 loss, and thus autophagy
induction, or negative regulation of autophagy inhibition, may be one
of the compensatory mechanisms that tumor cells use to counter-
balance the survival-undermining effects of autophagy suppression by
an activated PI3K/AKT/mTOR axis. Interestingly, germline mutations
in lkb1, tsc2 and pten tumor suppressor genes, all expected to activate
mTOR and suppress autophagy, result in hamartomatous syndromes
with common tumor biological characteristics [85]. At present, it isunclear whether defective autophagy plays any role in the pathogen-
esis and high malignancy potential of conditions, such as the Peutz–
Jeghers syndrome [86], tuberous sclerosis [87] and Cowden disease
[88], and, if yes, whether pharmacologic upregulation of autophagy
may play a disease- and cancer-preventative role for affected patients.
6.3. Role of apoptosis
The potential for crosstalk between apoptosis and autophagy was
ﬁrst recognized when Beclin 1 was initially identiﬁed as a Bcl-2-
interacting protein [33]. Apoptosis and autophagy share similarities in
that both are self-degradative cellular pathways activated under
conditions of stress. Apoptosis is a tightly regulated cell death
mechanism (type I cell death) activated to eliminate unwanted or
irreparably damaged cells, whereas autophagy involves cellular “self-
digestion”, as a stress adaptive response to prolong cell survival.
Similarly to apoptosis, autophagy can potentially lead to cell death, if
allowed to proceed to completion (hence, autophagic or type II cell
death). Regulators of apoptosis, such as Bcl-2/Bcl-xL and the BH3-only
proteins, interact with Beclin 1 and can modulate autophagy (Fig. 1).
The anti-apoptotic protein Bcl-2 binds to Beclin 1 under non-stress
conditions and inhibits autophagy in the ER [89], whereas the BH3-
only protein Bad [47], BNIP3 [90], and BH3 mimetics, such as ABT737
[47], competitively inhibit the interaction between Beclin 1 and Bcl-2/
Bcl-xL and stimulate autophagy. Thus, positive regulators of apoptosis
also induce autophagy, which is not very surprising given that both
pathways are activated under similar stress conditions. The functional
relationship between autophagy and apoptosis is complicated by the
fact that there is an apparent hierarchy in the activation and execution
of these two stress-responsive pathways. Apoptosis-competent cells
tend to undergo a rapid, “clean” apoptotic cell death under severe
stress with hardly any signs of autophagy activation, whereas cells
with apoptosis defects can sustain prolonged stress by upregulating
autophagy [13,15–17]. On the other hand, when autophagy is blocked,
apoptosis is accelerated [40,91] or apoptosis-defective cells undergo
metabolic catastrophe and die by necrosis [15,92]. Thus, cell fate in
response to metabolic stress is determined by the functional status
and the interaction between the stress-mitigating pathways of
apoptosis and autophagy [65].
6.4. Calcium signaling
Calcium (Ca2+) is a pluripotent intracellular signaling ion and an
ubiquitous second messenger that plays an essential role in many
processes, including muscle contraction, motility, metabolism, gene
expression, enzyme activity, cell proliferation and cell death [93,94].
Ca2+ signaling pathways are often remodeled or deregulated in
cancer, but whether these changes are required for tumorigenesis
remains to be determined [95]. An increase in free cytosolic Ca2+
concentration ([Ca2+]c) induces autophagy via activation of the Ca2+/
calmodulin-dependent kinase kinase-β (CaMKKβ), which then
activates AMPK that ultimately inhibits mTOR [96] (Fig. 1). Increased
[Ca2+]c also stimulates death-associated protein kinases (DAPKs) and
calpains, which are enzyme families linked to both autophagy [97–99]
(Fig. 1) and cancer [100,101] regulation. The implications of calcium-
mediated autophagy for tumorigenesis are not yet known.
6.5. Role of endoplasmic reticulum (ER)-stress
The ER is responsible for the folding and quality control of proteins
destined to be used in cell membranes, such as transmembrane
receptors and other integral membrane proteins, or to be exocytosed.
Accumulation of misfolded or unfolded proteins in the ER (ER-stress)
in response to diverse cellular insults has recently been shown to
upregulate autophagy via protein kinase-like endoplasmic reticulum
kinase (PERK), inositol-requiring kinase 1 (IRE1) and increased [Ca2+]c-
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ER-stress and the resultant unfolded protein response (UPR), such as
hypoxia and glucose deprivation, are frequently encountered in
rapidly growing tumors. In general, ER-stress and UPR activation can
be considered double-edge swords in cancer progression: they may
initiate apoptosis and promote tumor cell death, but they may also
upregulate tumor cell adaptive responses, rendering tumors more
aggressive by increasing their resistance to metabolic stress, and
possibly to chemotherapeutic agents, and enabling them to metas-
tasize more efﬁciently. Autophagy induction in tumors under
conditions of ER-stress, though not yet documented, likely occurs
as such an adaptive mechanism and potentially represents a novel
target that can be exploited for therapeutic beneﬁt.
6.6. Ras/RAF1/MEK1/2/ERK1/2 pathway
Ras is frequently mutated and constitutively activated in human
cancer, more frequently in pancreatic, colon, lung and thyroid tumors
[104]. Ras appears to regulate autophagy in a dual manner: it inhibits
autophagy by activating class I PI3K and the AKT/mTOR pathway
[105–107], and at the same time, it may induce autophagy via the
RAF1/MEK1/2/ERK1/2 pathway [108] (Fig. 1). The impact of Ras
activation on the functional status of autophagy in tumors has not yet
been determined. Also, whether autophagy modulation by Ras plays
any role in the tumorigenicity conferred by this oncogene remains to
be determined. Valid arguments can be made for either scenario:
autophagy inhibition may accelerate Ras-mediated tumorigenesis by
the cell-autonomous and/or non-cell-autonomous mechanisms
described earlier, whereas autophagy stimulation may provide Ras-
transformed tumor cells with a survival beneﬁt under rapid growth
conditions or treatment-induced metabolic stress.
7. Autophagy as a therapeutic target in cancer
The role and regulation of autophagy in cancer is apparently quite
complex, making autophagy a challenging, but potentially very
important, target for cancer prevention and treatment. In tumors,
autophagy is activated in areas of hypoxia and sustains tumor cell
survival under metabolic stress conditions [15,16]. Thus, autophagy
induction seen in response to anticancer agents mostly represents a
survival mechanism activated to counteract the deleterious effects of
endogenous metabolic stress and possibly also treatment on tumor
cells. On the other hand, when autophagy proceeds to completion, cell
death ensues raising the possibility that excessive autophagy induced
by drugs can potentially result in tumor cell elimination. Regarding
cancer prevention, the function of autophagy as a protector of cellular
homeostasis and genome integrity may be particularly important.
7.1. Modulation of autophagy for cancer treatment
7.1.1. Autophagy as a treatment resistance mechanism
7.1.1.1. Treatment of autophagy-competent tumors. Autophagy-com-
petent tumors may activate autophagy as an adaptive response to
anticancer agents, in which case autophagy may act as a treatment
resistance mechanism prolonging tumor cell survival. In this case,Table 1
Clinical trials utilizing hydrochloroquine to modulate autophagy in cancer therapy.
Clinical trials
HCQ and bortezomib in relapsed or refractory multiple myeloma (NCT00568880)
HCQ, RT and temozolomide in patients with glioblastoma multiforme (NCT00486603)
Ixabepilone and HCQ in metastatic breast cancer (NCT00765765)
HCQ, carboplatin, paclitaxel and bevacizumab in advanced lung cancer (NCT00728845)
HCQ in patients with PSA progression after local therapy for prostate cancer (NCT0072659concurrent inhibition of autophagy is expected to deprive cancer cells
of an essential coping mechanism, and, thus, enhance the efﬁcacy of
anticancer drugs. Given that apoptosis-defective cancer cells rely on
autophagy for survival under metabolic stress, in contrast to tumors
with intact apoptosis which may undergo rapid apoptotic cell death
when stressed, it is also expected that autophagy inhibitionwill likely
be therapeutically more beneﬁcial in the treatment of tumors with
apoptosis defects, but functional autophagy. Furthermore, the higher
metabolic demands of rapidly proliferating cancer cells may render
these cells “addicted” to autophagy for survival, and, consequently,
more vulnerable to autophagy inhibition than normal cells, a concept
that can be exploited for preferential tumor cell killing and reduction
of undesired treatment side-effects. Autophagy inhibition as a means
to sensitize cancer cells to treatment has been validated in several
studies: inhibition of autophagy by chloroquine, a lysosomotropic
agent that raises intralysosomal pH and interferes with autophago-
some degradation within lysosomes, was shown to enhance the
anticancer activity of the alkylating agent cyclophosphamide in amyc-
induced lymphoma model [109] and to induce p53-dependent cell
death and tumor suppression in different myc-induced and atm-
deﬁciency lymphoma models [110]; both chloroquine and 3-methyl-
adenine (3-MA), a class III PI3K inhibitor, synergistically augmented
the proapoptotic effects and overall anticancer activity of the histone
deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in
chronic myelogenous leukemia (CML) cells [111]; targeting autophagy
was used to circumvent TRAIL-resistance in tumors with apoptosis
defects [112]; knockdown of autophagy, in combination with
tamoxifen or 4-hydroxy-tamoxifen (4-OH-T), resulted in decreased
cell viability of estrogen receptor-positive MCF-7 and T-47D cells
[113,114]; inhibition of autophagy along with irradiation lead to
enhanced cytotoxicity of radiotherapy in resistant cancer cells [115].
The translational testing of this paradigm has already begun in a few
US institutions. Table 1 from the National Cancer Institute (NCI)
website (http://clinicaltrials.gov) lists trials actively accruing patients
in the USA that utilize hydroxychloroquine (HCQ) to modulate
autophagy for therapeutic beneﬁt in cancer.
7.1.1.2. Treatment of autophagy-deﬁcient tumors. Chronically autop-
hagy-deﬁcient tumors likely adjust to their autophagy-defective
status over time and acquire compensatory cell survival mechanisms.
Thus, cancer cells with autophagy defects are not expected to
depend on autophagy for cytoprotection during chemotherapy and
radiotherapy, in which case autophagy inhibition may not augment
the cytotoxicity conferred by anticancer drugs and irradiation. On the
other hand, autophagy-deﬁcient tumor cells likely exhibit increased
susceptibility to metabolic stress, high levels of DNA damage and
propensity toward genomic instability [16,17], all properties with
distinct implications for treatment responsiveness. Though not yet
documented, autophagy-defective tumors may be particularly
sensitive to metabolic stress-inducing regimens, such as anti-
angiogenic drugs, growth factor receptor inhibitors and glucose
deprivation, and to DNA damage-inducing agents, including plati-
num compounds and topoisomerase inhibitors. Defective autophagy
may not only sensitize tumor cells to certain drugs, but it may also
confer resistance to agents inducing gene ampliﬁcation as a
resistance mechanism. In the latter case, methotrexate may provePrincipal investigator, lead institution
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hypothesis that remains to be tested. Elucidation of the molecular
pathways compensating for tumor cell survival under conditions of
inactivated autophagy and determination of the mechanisms
responsible for the genomic instability exhibited by autophagy-
deﬁcient tumors will be critical for identifying novel therapeutic
targets in the treatment of such malignancies.
7.1.2. Autophagy as a cell death mechanism
Accumulation of autophagosomes in dying cells has, in many
occasions, been described as an active cell death mechanism. Along
the same thinking, autophagy induction by anticancer agents has been
considered a mediator of cytotoxicity, rather than drug resistance as
described in the previous section. Although “self-eating” by autop-
hagy can potentially lead to cell death when cytoplasmic material and
cellular organelles are consumed beyond a critical-for-cell-survival
point, in most cases, it is unclear whether autophagy represents an
active dying mode or the cell's desperate, and often exhausted,
attempt to survive. Complicating matters further, autophagy is usually
not observed in cells with intact apoptosis, as these cells undergo
rapid, apoptotic cell death under stress. As explained earlier,
autophagy becomes apparent as a survival mechanism mostly in an
apoptosis-defective background [13,15,16], thus tumor cells exhibiting
signs of treatment-induced autophagy likely have inherent apoptotic
defects and cannot undergo cell death characterized by classic signs of
apoptosis. In this case, non-apoptotic cell death occurs via alternative
death pathways, including necrosis [15,16] and possibly autophagy
[116]. The active role of autophagy as a cell deathmechanism can be in
principle validated by experiments documenting prolongation of cell
survival upon autophagy downregulation. This has been successfully
demonstrated in a few occasions [117–119]. However, in most cases,
autophagy inhibition under conditions of stress reduces cell viability
[13,15,120], and changes the mode of cell death to either apoptosis
[40,91] or necrosis [15,16], making a strong argument against this
hypothesis.
7.2. Modulation of autophagy for cancer prevention
Basal autophagy plays a critical role in cellular homeostasis, as it is
responsible for the degradation of excessive or malfunctioning
organelles and damaged or misfolded proteins [2,3]. Accumulation
of protein aggregates due to defective autophagy plays a central role in
neurodegeneration, including Alzheimer's, Parkinson's and polyglu-
tamine diseases, and in hepatic dysfunction, but whether it also
contributes to cancer development and progression is not yet clear. A
reasonable hypothesis is that protein aggregation in autophagy-
defective tumor cells is a likely source of genotoxic stress, including
ER- and oxidative-stress, in turn contributing to the genomic damage
and instability, and thus increased tumorigenicity, associated with
autophagy defects. The prediction would then be that autophagy
induction, and thus maintenance of cellular ﬁtness, may be used for
cancer prevention, similarly to the rapidly evolving use of autophagy
stimulators for prevention of neurodegeneration [121].
8. Concluding remarks
There is no doubt that the role of autophagy in cancer is complex
and that much work is still needed to determine the molecular details
of autophagy regulation in tumor cells, deﬁne how the functional
status of autophagy in tumors impacts cancer progression and
response to treatment, and elucidate how to best modulate autophagy
for cancer prevention and therapeutic beneﬁt. Autophagy defects are
associated with susceptibility to metabolic stress, DNA damage
accumulation, genomic instability, and accelerated tumorigenicity,
and these observations lead to the predictions that autophagy
stimulation may preserve cellular ﬁtness and genome integrity, andthus prevent cancer, and that tumors with chronic autophagy
deﬁciency may be particularly sensitive to certain anticancer agents,
such as DNA-damaging and anti-angiogenic drugs. Tumors with intact
autophagy likely utilize and potentially rely on this pathway for
survival undermetabolic stress conditions, such as during rapid tumor
growth, metastasis and chemo- or radiotherapy. In this case, inhibition
of autophagy concurrently with treatment may augment the anti-
tumor activity, and thus the efﬁcacy, of radiation and/or anticancer
drugs. Ultimately, pharmacologic manipulation of autophagy for
cancer prevention and treatment will depend on our ability to
successfully recognize the functional status of autophagy in tumors
and on the availability of speciﬁc autophagy modulators.References
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